Two drugs better than one for children

Individual therapy that combines zidovudine (AZT) with lamivudine (3TC) is much more effective at delaying disease progression or death in children with symptomatic HIV infection, according to a large study supported by the National Institutes of Health.

The study, which was stopped early, shows that combination therapy should be the preferred treatment for children, particularly those over three years old and who have never been treated before.

"These results provide new hope for young children who develop symptomatic HIV disease," says Anthony Fauci, MD, MPH, director of the National Institute of Allergy and Infectious Diseases in Bethesda, MD. "This study clearly demonstrates that, as is the case with adults, combination therapy can significantly slow disease progression."